<P> P. aeruginosa is often preliminarily identified by its pearlescent appearance and grape - like or tortilla - like odor in vitro . Definitive clinical identification of P. aeruginosa often includes identifying the production of both pyocyanin and fluorescein, as well as its ability to grow at 42 ° C. P. aeruginosa is capable of growth in diesel and jet fuels, where it is known as a hydrocarbon - using microorganism, causing microbial corrosion . It creates dark, gellish mats sometimes improperly called "algae" because of their appearance . </P> <P> Many P. aeruginosa isolates are resistant to a large range of antibiotics and may demonstrate additional resistance after unsuccessful treatment . It should usually be possible to guide treatment according to laboratory sensitivities, rather than choosing an antibiotic empirically . If antibiotics are started empirically, then every effort should be made to obtain cultures (before administering first dose of antibiotic), and the choice of antibiotic used should be reviewed when the culture results are available . </P> <P> Due to widespread resistance to many common first - line antibiotics, carbapenems, polymyxins, and more recently tigecycline were considered to be the drugs of choice; however, resistance to these drugs has also been reported . Despite this, they are still being used in areas where resistance has not yet been reported . Use of β - lactamase inhibitors such as sulbactam has been advised in combination with antibiotics to enhance antimicrobial action even in the presence of a certain level of resistance . Combination therapy after rigorous antimicrobial susceptibility testing has been found to be the best course of action in the treatment of multidrug - resistant P. aeruginosa . Some next - generation antibiotics that are reported as being active against P. aeruginosa include doripenem, ceftobiprole, and ceftaroline . However, these require more clinical trials for standardization . Therefore, research for the discovery of new antibiotics and drugs against P. aeruginosa is very much needed . Antibiotics that may have activity against P. aeruginosa include: </P> <Ul> <Li> aminoglycosides (gentamicin, amikacin, tobramycin, but not kanamycin) </Li> <Li> quinolones (ciprofloxacin, levofloxacin, but not moxifloxacin) </Li> <Li> cephalosporins (ceftazidime, cefepime, cefoperazone, cefpirome, ceftobiprole, but not cefuroxime, cefotaxime, or ceftriaxone) </Li> <Li> antipseudomonal penicillins: carboxypenicillins (carbenicillin and ticarcillin), and ureidopenicillins (mezlocillin, azlocillin, and piperacillin). P. aeruginosa is intrinsically resistant to all other penicillins . </Li> <Li> carbapenems (meropenem, imipenem, doripenem, but not ertapenem) </Li> <Li> polymyxins (polymyxin B and colistin) </Li> <Li> monobactams (aztreonam) </Li> </Ul>

What is the drug of choice for pseudomonas